<DOC>
	<DOCNO>NCT00352885</DOCNO>
	<brief_summary>This study determine effectiveness antidepressant prevent reduce depressive symptom people melanoma receive Interleukin-2 ( IL-2 ) treatment .</brief_summary>
	<brief_title>Evaluating Effectiveness Escitalopram Preventing Reducing Depressive Symptoms People Receiving Interleukin-2 Treatment</brief_title>
	<detailed_description>Melanoma serious type skin cancer , affect nearly 54,000 people United States year . Melanomas often develop pre-existing mole new mole body . If leave untreated , cancerous cell spread throughout body . Fortunately , melanoma cure person diagnose treat early . Typical treatment include surgery , amputation , chemotherapy , immunotherapy . Interleukin-2 ( IL-2 ) treatment , type immunotherapy , use body 's immune system slow stop spread cancer cell part body . However , IL-2 treatment typically associate severe side effect , include depression , fatigue , difficulty thinking . This study evaluate whether escitalopram , antidepressant , help improve treatment-related depressive symptom , reduce stress hormone level , increase number treatment cycle among people metastatic melanoma receive IL-2 treatment . Participation double-blind study last 18 week include 5 14 study visit . Participants complete four 1-week cycle IL-2 treatment 12-week period . Two week prior start IL-2 treatment , participant undergo psychiatric interview ; computerize thinking test ; questionnaire ; blood , urine , saliva collection . Participants also randomly assign start receive either escitalopram placebo entire duration study . The dosage escitalopram placebo vary depend symptom severity participant . Immediately prior IL-2 treatment , participant undergo preliminary IL-2 procedure , include medical history review , physical exam , blood collection . These procedure occur every day participant hospital IL-2 treatment . Participants stay hospital receive four IL-2 treatment cycle . During hospital stay , participant complete repeat questionnaire computerize task . Blood collection occur select times well . A follow-up visit occur 4 week final treatment dose IL-2 .</detailed_description>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Diagnosed cancer begin Interleukin ( IL ) 2 treatment Willing use effective form birth control throughout study sexually active Diagnosed major depression experience significant depressive symptom Hamilton Rating ScaleDepression score 18 high Brain metastasis , history brain injury , seizure disorder Meets Diagnostic Statistical Manual Mental Disorders ( DSM ) IV criterion substance abuse dependence within 3 month study entry Suicidal , psychotic , receive psychiatric hospitalization within 12 month study entry Past current history schizophrenia bipolar disorder Pregnant planning become pregnant within 1 2 year Evidence untreated poorly control infectious , hormone , heart , blood , kidney , liver , neurological disease Use antidepressant , glucocorticoid , guanethidine , centrally act alphaantagonists , betablockers , anticonvulsant Clinically significant eye abnormalities A score lower 28 Mini Mental Status Exam ( MMSE ) Prior history severe adverse event associate escitalopram selective serotonin reuptake inhibitor ( SSRI ) antidepressant Diagnosed type 1 type 2 diabetes Any condition might make participant unsuitable enrollment could interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>IL-2 therapy</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Immune system</keyword>
	<keyword>Neuroendocrine response</keyword>
</DOC>